Novavax Statistics
Total Valuation
Novavax has a market cap or net worth of $1.44 billion. The enterprise value is $1.05 billion.
Important Dates
The last earnings date was Wednesday, August 6, 2025, before market open.
| Earnings Date | Aug 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Novavax has 162.42 million shares outstanding. The number of shares has increased by 30.54% in one year.
| Current Share Class | 162.42M |
| Shares Outstanding | 162.42M |
| Shares Change (YoY) | +30.54% |
| Shares Change (QoQ) | -0.23% |
| Owned by Insiders (%) | 0.50% |
| Owned by Institutions (%) | 50.47% |
| Float | 136.72M |
Valuation Ratios
The trailing PE ratio is 3.48.
| PE Ratio | 3.48 |
| Forward PE | n/a |
| PS Ratio | 1.26 |
| Forward PS | 3.82 |
| PB Ratio | 36.55 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 2.49 |
| EV / Sales | 0.98 |
| EV / EBITDA | 2.59 |
| EV / EBIT | 2.88 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.36, with a Debt / Equity ratio of 6.07.
| Current Ratio | 2.36 |
| Quick Ratio | 2.16 |
| Debt / Equity | 6.07 |
| Debt / EBITDA | 0.56 |
| Debt / FCF | n/a |
| Interest Coverage | 15.55 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 14.52% |
| Return on Invested Capital (ROIC) | 467.59% |
| Return on Capital Employed (ROCE) | 38.67% |
| Revenue Per Employee | $1.13M |
| Profits Per Employee | $444,143 |
| Employee Count | 952 |
| Asset Turnover | 0.68 |
| Inventory Turnover | 47.58 |
Taxes
In the past 12 months, Novavax has paid $8.56 million in taxes.
| Income Tax | 8.56M |
| Effective Tax Rate | 1.98% |
Stock Price Statistics
The stock price has decreased by -25.32% in the last 52 weeks. The beta is 2.50, so Novavax's price volatility has been higher than the market average.
| Beta (5Y) | 2.50 |
| 52-Week Price Change | -25.32% |
| 50-Day Moving Average | 7.08 |
| 200-Day Moving Average | 7.72 |
| Relative Strength Index (RSI) | 67.10 |
| Average Volume (20 Days) | 7,569,061 |
Short Selling Information
The latest short interest is 42.31 million, so 26.05% of the outstanding shares have been sold short.
| Short Interest | 42.31M |
| Short Previous Month | 43.08M |
| Short % of Shares Out | 26.05% |
| Short % of Float | 30.95% |
| Short Ratio (days to cover) | 8.53 |
Income Statement
In the last 12 months, Novavax had revenue of $1.08 billion and earned $422.82 million in profits. Earnings per share was $2.54.
| Revenue | 1.08B |
| Gross Profit | 616.86M |
| Operating Income | 366.39M |
| Pretax Income | n/a |
| Net Income | 422.82M |
| EBITDA | 407.51M |
| EBIT | 366.39M |
| Earnings Per Share (EPS) | $2.54 |
Full Income StatementBalance Sheet
The company has $612.30 million in cash and $228.49 million in debt, giving a net cash position of $383.81 million or $2.36 per share.
| Cash & Cash Equivalents | 612.30M |
| Total Debt | 228.49M |
| Net Cash | 383.81M |
| Net Cash Per Share | $2.36 |
| Equity (Book Value) | 37.63M |
| Book Value Per Share | 0.23 |
| Working Capital | 530.37M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$630.94 million and capital expenditures -$4.77 million, giving a free cash flow of -$635.71 million.
| Operating Cash Flow | -630.94M |
| Capital Expenditures | -4.77M |
| Free Cash Flow | -635.71M |
| FCF Per Share | -$3.91 |
Full Cash Flow StatementMargins
Gross margin is 57.18%, with operating and profit margins of 33.96% and 39.20%.
| Gross Margin | 57.18% |
| Operating Margin | 33.96% |
| Pretax Margin | 39.99% |
| Profit Margin | 39.20% |
| EBITDA Margin | 37.78% |
| EBIT Margin | 33.96% |
| FCF Margin | n/a |
Dividends & Yields
Novavax does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -30.54% |
| Shareholder Yield | -30.54% |
| Earnings Yield | 29.40% |
| FCF Yield | -44.20% |
Analyst Forecast
The average price target for Novavax is $15.33, which is 73.22% higher than the current price. The consensus rating is "Buy".
| Price Target | $15.33 |
| Price Target Difference | 73.22% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | -10.00% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
Stock Splits
The last stock split was on May 10, 2019. It was a reverse split with a ratio of 1:20.
| Last Split Date | May 10, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
Novavax has an Altman Z-Score of -1.72 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.72 |
| Piotroski F-Score | 5 |